Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conflict Of Interest Reform: With FDA Undecided, Consumer Groups Give Their Pitch

Executive Summary

FDA likes some rules in FDAAA and wants to continue discussion with Capitol Hill as changes are expected to be part of PDUFA legislation.

Advertisement

Related Content

CDER Advisory Panel Vacancies Remain High As Overall FDA Rates Improve
FDA Conflict Of Interest Screening Could Get Streamlined As Patient Involvement Increases
Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate
Did PDUFA V Pass Too Quickly?
Senate User Fee Bill Heads To Mark-up Without Track-And-Trace
Conflict Of Interest Rules Removed In Draft Of House User Fee Bill
FDA Intellectual Bias Policy Takes Wolfe Off Contraceptives Safety Review
Drug Shortage Bills Likely Drivers Of PDUFA Add-ons
PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter
FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules

Topics

Advertisement
UsernamePublicRestriction

Register

PS054102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel